DDInter1627 DDInter1628
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is associated with {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN1A
SCN1A {u} (Gene) interacts with {v} (Gene) PRPF3
PRPF3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is associated with {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) regulates {v} (Gene) ACOT9
ACOT9 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) binds {v} (Gene) GRM5
GRM5 {u} (Gene) interacts with {v} (Gene) PRKCE
PRKCE {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is associated with {v} (Gene) AKT1
AKT1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN9A
SCN9A {u} (Gene) regulates {v} (Gene) RPP38
RPP38 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) interacts with {v} (Gene) BMPR2
BMPR2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Rufinamide (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Rufinamide (Compound) binds SCN1A (Gene) and SCN1A (Gene) interacts with PRPF3 (Gene) and PRPF3 (Gene) is upregulated by Ruxolitinib (Compound)
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is associated with RET (Gene) and RET (Gene) is bound by Ruxolitinib (Compound)
Rufinamide (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) regulates ACOT9 (Gene) and ACOT9 (Gene) is downregulated by Ruxolitinib (Compound)
Rufinamide (Compound) binds GRM5 (Gene) and GRM5 (Gene) interacts with PRKCE (Gene) and PRKCE (Gene) is bound by Ruxolitinib (Compound)
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is associated with AKT1 (Gene) and AKT1 (Gene) is downregulated by Ruxolitinib (Compound)
Rufinamide (Compound) binds SCN9A (Gene) and SCN9A (Gene) regulates RPP38 (Gene) and RPP38 (Gene) is upregulated by Ruxolitinib (Compound)
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) interacts with BMPR2 (Gene) and BMPR2 (Gene) is bound by Ruxolitinib (Compound)